Rohan Ganguli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11753100/publications.pdf

Version: 2024-02-01

172457 189892 2,901 53 29 50 citations h-index g-index papers 53 53 53 2519 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Research, 1994, 51, 1-10.	3.3	220
2	Electroencephalographic Sleep in Young, Never-Medicated Schizophrenics. Archives of General Psychiatry, 1987, 44, 36.	12.3	198
3	Web-Based Psychoeducational Intervention for Persons With Schizophrenia and Their Supporters: One-Year Outcomes. Psychiatric Services, 2010, 61, 1099-1105.	2.0	159
4	Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2005, 66, 205-212.	2.2	157
5	Nutritional Assessment of Patients With Schizophrenia: A Preliminary Study. Schizophrenia Bulletin, 2003, 29, 393-397.	4.3	149
6	Designing websites for persons with cognitive deficits: Design and usability of a psychoeducational intervention for persons with severe mental illness Psychological Services, 2007, 4, 202-224.	1.5	139
7	Mitogen-Stimulated Interleukin-2 Production in Never-Medicated, First-Episode Schizophrenic Patients. Archives of General Psychiatry, 1995, 52, 668.	12.3	131
8	Autoimmunity in Schizophrenia: A Review of Recent Findings. Annals of Medicine, 1993, 25, 489-496.	3.8	130
9	Increased Serum Interleukin 2 Receptor Concentration in Schizophrenic and Brain-Damaged Subjects. Archives of General Psychiatry, 1989, 46, 292.	12.3	119
10	Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophrenia Research, 2003, 62, 73-76.	2.0	115
11	Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis. Schizophrenia Research, 2007, 93, 90-98.	2.0	106
12	Decreased interleukin-2 production in schizophrenic patients. Biological Psychiatry, 1989, 26, 427-430.	1.3	85
13	Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. Schizophrenia Research, 2011, 126, 103-109.	2.0	85
14	Altered interleukin-2 production in schizophrenia: Association between clinical state and autoantibody production. Psychiatry Research, 1992, 44, 113-123.	3.3	77
15	Immune Abnormalities in Schizophrenia: Evidence for the Autoimmune Hypothesis. Harvard Review of Psychiatry, 1994, 2, 70-83.	2.1	71
16	Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophrenia Research, 2006, 86, 269-275.	2.0	64
17	Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders (WAIST Study). Schizophrenia Research, 2013, 145, 63-68.	2.0	63
18	Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biological Psychiatry, 1991, 30, 731-735.	1.3	61

#	Article	IF	CITATIONS
19	Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders. Journal of Psychiatric Research, 1995, 29, 303-314.	3.1	56
20	Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophrenia Research, 2005, 76, 343-351.	2.0	52
21	PET brain mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia. Biological Psychiatry, 1997, 41, 33-42.	1.3	47
22	Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research, 2001, 49, 261-267.	2.0	47
23	Monitoring and Managing Weight Gain in the Mentally Ill. Journal of Clinical Psychiatry, 2007, 68, e14.	2.2	47
24	Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. Biological Psychiatry, 1987, 22, 1488-1491.	1.3	42
25	Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophrenia Research, 2005, 75, 425-432.	2.0	40
26	Rationale and strategies for switching antipsychotics. American Journal of Health-System Pharmacy, 2002, 59, S22-S26.	1.0	33
27	Negative association of schizophrenia with HLA DQB1*0602: Evidence from a second African-American cohort. Schizophrenia Research, 1997, 23, 81-86.	2.0	32
28	Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study. BMC Medicine, 2008, 6, 17.	5.5	32
29	Impaired mitogen (PHA) responsiveness and increased autoantibodies in caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biological Psychiatry, 1995, 37, 546-549.	1.3	31
30	Addressing cardiometabolic risk during treatment with antipsychotic medications. Current Opinion in Psychiatry, 2008, 21, 613-618.	6.3	31
31	Non-right sidedness: An association with lower IL-2 production. Life Sciences, 1992, 51, 1843-1849.	4.3	27
32	Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biological Psychiatry, 1992, 32, 735-738.	1.3	23
33	CD5 positive B lymphocytes in schizophrenia: No alteration in numbers or percentage as compared with control subjects. Psychiatry Research, 1993, 48, 69-78.	3.3	23
34	Hydrocortisone induced regional cerebral activity changes in schizophrenia: a PET scan study. Schizophrenia Research, 2002, 56, 241-247.	2.0	20
35	Electroencephalographic sleep and cerebral morphology in functional psychoses: A preliminary study with computed tomography. Psychiatry Research, 1991, 39, 293-301.	3. 3	19
36	Elevated IGG anti-histone antibodies in a subgroup of medicated schizophrenic patients. Schizophrenia Research, 1992, 7, 49-54.	2.0	18

#	Article	IF	CITATIONS
37	Evaluating the accuracy, quality, and readability of online physical activity, exercise, and sport information for people with schizophrenia. Mental Health and Physical Activity, 2013, 6, 95-99.	1.8	18
38	Prevention of Metabolic Syndrome in Serious Mental Illness. Psychiatric Clinics of North America, 2011, 34, 109-125.	1.3	17
39	Behavioral therapy for weight loss in patients with schizophrenia. Journal of Clinical Psychiatry, 2007, 68 Suppl 4, 19-25.	2.2	17
40	Body composition, preâ€diabetes and cardiovascular disease risk in early schizophrenia. Microbial Biotechnology, 2017, 11, 229-236.	1.7	16
41	Changes in Weight and other Metabolic Indicators in Persons with Schizophrenia Following a Switch to Aripiprazole. Clinical Schizophrenia and Related Psychoses, 2011, 5, 75-79.	1.4	16
42	Testing a modification of cognitive adaptation training: Streamlining the model for broader implementation. Schizophrenia Research, 2014, 156, 46-50.	2.0	15
43	Are older antipsychotic drugs obsolete?. BMJ: British Medical Journal, 2006, 332, 1346-1347.	2.3	12
44	The prevalence of autoantibodies among right and left handed schizophrenic patients and control subjects. Biological Psychiatry, 1992, 32, 803-811.	1.3	11
45	Health-related quality of life, adiposity, and sedentary behavior in patients with early schizophrenia: preliminary study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012, 5, 389.	2.4	9
46	Weight Loss Interventions for Patients with Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2007, 1, 43-53.	1.4	7
47	Diabetes Resolution Following Discontinuation of a Second-Generation Antipsychotic. Clinical Schizophrenia and Related Psychoses, 2013, 6, 202-203.	1.4	5
48	Dietary intake of patients with schizophrenia. Psychiatry, 2005, 2, 31-5.	0.3	4
49	Differences in serum interleukin-6 (IL-6) between healthy dextral and non-dextral subjects. Neuroscience Research, 1994, 20, 185-188.	1.9	3
50	Autoimmunity as a factor in the pathogenesis of schizophrenia. Clinical Immunology Newsletter, 1988, 9, 74-76.	0.1	2
51	Smoking Affects Plasma-Soluble Interleukin-2 Receptor Levels in Patients With Schizophrenia-Reply. Archives of General Psychiatry, 1997, 54, 89.	12.3	0
52	Assessing Online Dietary Information for People With Schizophrenia. Psychiatric Services, 2014, 65, 1286-1286.	2.0	0
53	HLA and Psychiatric Disease. , 2000, , 419-426.		0